Form 4: Cardio Diagnostics Director Acquires Stock Options

Peter K. Fung, a Director at Cardio Diagnostics Holdings, Inc., acquired stock options on June 30, 2026, as detailed in a Form 4 filing.

Summary

• Peter K. Fung, a Director of Cardio Diagnostics Holdings, Inc. (CDIO), acquired stock options on June 30, 2026.
• The transaction involved the acquisition of 2,854 stock options with an exercise price of $2.19.
• These options are exercisable from June 30, 2026, and expire on June 30, 2036.
• Following this transaction, Mr. Fung beneficially owns 12,367 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider transaction of stock options, indicating potential future upside without immediate financial impact.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price suggests a potential for future stock appreciation.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future stock performance, as the options have value only if the stock price increases above the exercise price.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology and healthcare sectors, often used as a form of executive compensation and to align management interests with shareholder value.

Stakeholder Impact

• Shareholders may view the director's acquisition of options positively, as it aligns management's interests with potential stock appreciation.

Key Dates

Keywords

Cardio Diagnostics Holdings, CDIO, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Director Transaction